With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

The gene therapy for an undisclosed central nervous system disease is based on JCR's delivery technology and Modalis' epigenome editing platform.

NEW YORK – BeiGene last week said the US Food and Drug Administration approved its anti-PD-1 monoclonal antibody Tevimbra (tislelizumab) with platinum and fluoropyrimidine-based chemotherapy as a ...

The grants, awarded in partnership with the Authority of Social Contribution-Ma'an, will fund 11 research projects across multiple disease areas.

Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

NEW YORK – The European Commission has expanded the indication for Johnson & Johnson's EGFR-MET bispecific antibody Rybrevant (amivantamab) in combination with the EGFR tyrosine kinase inhibitor ...

NEW YORK – Hutchmed said on Thursday that the new drug application (NDA) for its c-MET inhibitor Orpathys (savolitinib) with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for ...